How to judge a longevity provider: three filters and one honest question

Ethics gets talked about in this market as a value. It behaves like a constraint. It sits in the revenue mix, in the order things are sold, and in what a business could survive telling you.

When my earlier piece on the dirty secret of longevity found an audience, most readers took it for a swing at drips and gadgets. It wasn't. The target sits underneath the drip stand and it's much quieter. Across most of healthcare, nobody in the room gets paid to ask the one question that decides whether the money did anything at all: does this person need what is being sold, and will it leave them healthier once everything is counted?

Data and technology are both abundant, and both keep getting cheaper. What's missing is a commercial reason to answer that question honestly. In almost every model I've looked at, ethics is the ingredient you can leave out and still hit your numbers, at least for a while.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.

What kind of market this actually is

From far enough away the chart is beautiful. OECD countries put somewhere around nine to ten per cent of GDP into health, and the line points upward. The global wellness economy is worth several trillion and has been compounding at roughly twice the rate of global GDP in recent years, which makes it bigger than several sectors that get considerably more attention, including chunks of IT and of sport and recreation, and puts it within reach of the green economy in sheer scale. Inside it, the anti-ageing, aesthetic and longevity segments grow at mid to high single digits a year, and drip clinics, hydration bars and IV therapy have posted growth from high single into low double digits in plenty of markets.

Big market. Strong growth. Demand that barely flexes with price, because everyone ages and almost everyone is quietly afraid of decline. In any other sector the next question would be where that growth is mispriced.

The evidence is not evenly spread. We have strong, repeatable findings that a short list of unglamorous things cuts cardiovascular events, disability and early death: getting blood pressure under control, raising cardiorespiratory fitness, keeping people physically active, and screening at the intervals guidelines actually support. The effect sizes there are large. We have much weaker evidence, and in places none at all, that vitamin infusions, most peptides and open-ended optimisation protocols do anything durable for an otherwise healthy person beyond placebo and a pleasant afternoon, and those still carry real cost and real risk.

Capital flows almost entirely toward the second list. Billions into aesthetics, infusions, aggressive imaging and data-rich experiences. Comparatively little into behaviour-heavy prevention built to the evidence. Investors aren't being stupid. They're responding correctly to a market whose structure makes that the rational bet.

Three features do the work. Health is a credence good, so you almost never find out whether the thing you paid for changed anything. Information is asymmetric, so the seller appears to know more than you and usually does. And the externalities are enormous, because most of the value prevention creates lands on the public system, on employers and on families rather than on whoever settled the invoice. Put those three together and selling something that merely sounds plausible becomes cheap, while selling only what works becomes expensive.

Growth that looks brilliant on a slide

This pattern isn't new and it isn't unique to health. Adtech optimised clicks and time on site rather than whether anybody ended up better off. Subprime lending optimised yield in the current year and pushed solvency into a later one. Green finance produced speculative carbon products that grew considerably faster than any actual decarbonisation. Every one of those verticals looked excellent in a deck. Underneath, a meaningful share of the growth came from exploiting what buyers couldn't see and from moving risk into the future.

Longevity is drifting down the same road. Infusion chains, hotels selling wellness by the week, memberships built around a whole-body scan: each of those is simple to explain to an investor, simple to franchise, simple to sell. Prevention, and the risk architecture that makes prevention specific to one person, is harder to explain, slower to earn from, and stubbornly resistant to the kind of scaling a pitch deck rewards.

Read as an allocation problem, the sector is over-invested in high-margin, low-evidence private goods: the infusions, the vanity diagnostics, the annual executive package. It's under-invested in lower-margin, high-evidence goods whose benefits spill outward: blood pressure, fitness, sleep, mental health, and prevention done the way guidelines describe. The money is going into the theatre rather than the engine.

Three structural failures, described as a system rather than a scandal

I want to make this argument without moralising, because moralising lets everyone off. Most people working inside these businesses are conscientious. The failures are structural, which is the worse news, since structures don't respond to good intentions.

Informed consent is a thin patch over an information gap

In theory, consent closes the gap. Risks and benefits are disclosed, the person decides, the asymmetry is neutralised on paper. In a premium longevity setting, three things reliably break that.

The first is complexity. Full-body MRI, genomic panels, layered omics, peptide stacks. Clinicians struggle to stay current with the evidence across all of it. A client sitting in the consultation has no chance at all.

The second is narrative demand, and it comes from the buyer. Someone paying eight to twenty thousand euros a year for a membership rarely wants to be told that the answer is mostly sleep, walking, lifting and one statin. The story has to feel proportional to the price. A complicated account sells better than a true one, and the person buying is often an active participant in that.

The third is the sales overlay. The consultation runs half clinical and half commercial, because direct-to-consumer playbooks have been imported wholesale into clinical rooms. The question genuinely being answered concerns how to frame something so you feel good about buying it. Every formality is observed. The economic logic underneath goes untouched.

The conflict of interest lives in the revenue mix

Health economics has known the shape of this for decades. Where physicians own the imaging equipment, imaging rates rise. Fee-for-service models tend to push volume up without a matching improvement in what happens to people afterwards. None of that is scandalous. It's textbook principal-agent behaviour.

Longevity clinics have rebuilt the same machine under better lighting. The margin sits in infusions, injectables, niche diagnostics and high-ticket packages. The internal metrics are revenue per square metre, how busy each device is, and conversion. An upgrade earns a member of staff more than talking somebody out of something they didn't need.

I'm not describing this from a safe distance. An early Atlas Cove financial model carried a line which, translated out of spreadsheet language, said that a set share of arriving guests ought to have an infusion or an injection on the books before their first day was over. On a spreadsheet that reads as sound planning. Fixed costs are high, the margin lives in particular services, and guests turn up expecting something to happen. Read it as an economist and it's precisely what you'd criticise anywhere else: a direct financial reward for overselling a good the buyer cannot verify. Every time a clinician says the words "you don't need that", contribution margin falls. Under that design, honesty carries negative economics, and nobody has to behave badly for the outcome to arrive.

Nobody owns the decade

Almost every health business owns a very short slice of a person's trajectory. A hospital is measured on thirty-day readmissions and acute complications. A longevity clinic is measured on monthly revenue, annual renewal and its satisfaction score.

The interventions with the strongest evidence pay out on a completely different clock. Blood pressure held in range for years, lipids properly managed, physical activity sustained, cancer screening done when it's genuinely indicated: those move hard endpoints across five to twenty years, not five to twenty days. So the sector optimises for what it can measure and sell inside a quarter and quietly neglects ten-year risk, which is hard to attribute to anybody and harder still to bill for.

That mismatch is how you get growth in the double digits for aggressive screening and whole-body check-ups at the same time as epidemiologists warn that screening general populations outside defined risk groups tends to produce more findings and more procedures without moving mortality. We're effectively paying businesses to manufacture data and anxiety rather than to prevent strokes and amputations.

What to ask before you sign anything

You don't have to evaluate the science yourself. You have to evaluate the structure, and three questions do most of that work. They're the same three filters we ran our own stack through, turned around and pointed at the seller.

1. Evidence tier. Ask which tier each recommendation sits in. Strong outcome data in humans. Early human data that looks promising. Mechanism and animal work alone. Or plain speculation. A serious provider answers without hesitating, and says so when something belongs in the bottom two tiers.

2. Net benefit by profile. Ask for whom, exactly, this materially changes long-term risk or function, and at which stage. "It's good for everyone" is not an answer.

3. Sequence. Ask whether this belongs before or only after the boring work: sleep, blood pressure, lipids, fitness, mental health, weight where that applies, and screening done to guideline. Where imaging, injectables or an exotic panel arrive before anyone has looked seriously at those, the order is wrong, and the order is where the ethics live.

Red flag test: if the complexity of the story you're told scales neatly with the size of the invoice, that tells you about the pricing rather than about your biology. The inverse matters too. Somebody who says most of your gain sits in four dull things, and who therefore has far less to sell you, has just told you something expensive about themselves.

The rare market where the buyer can feel the product

This is the part that seldom survives into an investment memo. Most products hide behind brand and perception indefinitely. Health can't, at least not forever. If your sleep improves, you know. If your blood pressure comes under control and your fitness climbs, your body reports it back to you. If your background worry about your own decline drops because things genuinely are better, your behaviour shifts on its own. The utility here is embodied rather than believed, which is rare in a multi-trillion market.

A business that really does deliver fewer symptoms, more usable energy, better function and less risk ought to have far stickier economics than one delivering experiences and dashboards. In theory an evidence-first model should behave like a very good B2B software product. Retention runs high because leaving costs you something you can feel. Expansion happens by itself, because people who are genuinely better bring their spouses, their friends and their colleagues. Acquisition gets cheaper every year that reputation compounds. What the industry does instead resembles fashion retail: new protocols, new devices, customers circulating between providers, and the churn politely reframed as people trying different things. The open opportunity is a layer that earns its money from felt, durable health rather than from novelty.

Ethical debt, the line item nobody models

Operators and investors already carry a mental list: financial leverage, regulatory risk, reputational risk. This sector needs one more entry on it, and I've started calling that entry ethical debt.

It's the accumulated distance between the product set and sequence you know would be defensible and net positive, and the one you actually sell because it's profitable and because the market will currently accept it. You take it on when you add a performance infusion mainly because it photographs well, when you keep a high-billing clinician whose numbers depend on selling more than is needed, when you push general check-ups and scans outside their evidence-based indications, or when prevention becomes a marketing layer sitting over an engine that runs on something else entirely.

It behaves like technical debt in three ways. Correcting course later is expensive. It compounds quietly, so nobody notices the balance until it's already large. And it eventually crystallises, usually as a scandal, a regulator, or the quiet departure of the best people on the team. Technical debt is repaid in engineering hours. This one is repaid in human bodies.

Seen the way an economist sees it, ethical debt is a liability nobody prices, in a sector whose two scarcest assets happen to be trust and outcomes that only appear after decades. Carrying heavy ethical leverage in a credence market is more than morally questionable. It's financially naive.

The one question I use on any longevity business

Boundary: here's the line I now apply to myself first and to every other operator second. Could this company still function if every clinician in it told every client the entire truth about what they need, up to and including the sentence "you don't need most of what we sell"?

Where the honest answer is no, the thing being valued isn't a healthcare company. It's an extraction scheme built on top of an information gap, and it deserves to be priced as one. That model can be very profitable. Plenty of profitable things are. The point is knowing which of the two you're buying, a membership or a stake.

Two caveats, because this argument gets stretched further than I mean it. First, none of it makes tools at the frontier illegitimate. Frontier imaging, drugs aimed at a specific target and protocols still under study all have real places, and gating something is a long way from banning it. What I object to is selling those things first, to everybody, before there's evidence for that particular person. Second, the criticism of broad screening is a criticism of indication rather than of the test itself. The right investigation for the right person at the right moment is good medicine. The identical investigation sold to every new arrival on day one is a revenue tactic wearing a white coat.

The wellness sector already runs into the trillions, prevention carries a clear and measurable return, and health is one of the very few things people feel in their own bodies. So the compounding opportunity sits somewhere other than the theatre. It sits in whichever layer proves capable of directing that growing river of spending toward what genuinely adds healthy, capable years.

What this looks like when somebody builds it

I started Atlas Cove because criticising this market while quietly rebuilding it in nicer stone was not a thing I could live with. We began where everybody begins: advanced imaging on the whiteboard, elaborate panels, a long and genuinely exciting list of tools at the frontier. Then the stack went through the three filters above, and a great many attractive lines died on that whiteboard.

What survived is arranged in three layers, and the order is the entire point.

Foundations, which are not optional. Everyone starts in a structured foundations phase: movement and strength, cardio built around VO2 max in a form that fits a real week, sleep and circadian rhythm, the metabolic and nutritional basics, and the mental load carried by work and relationships. These are the levers with the largest and clearest effect on illness and death in the literature. Skipping them to reach the frontier makes no sense if outcomes matter more than optics.

A medical and prevention layer aligned to the evidence. On top of the foundations sit basic labs through a quality partner laboratory, covering lipids, glucose and HbA1c, organ function, and inflammatory markers where they're relevant. Then vitals and functional measures: blood pressure, resting heart rate, strength, straightforward cardio tests. Decisions about medication and screening follow guidelines, with specialist input where it's needed. Physicians who work in prevention read the results, inside clear regulation, and the evidence tier gets stated out loud every time.

A frontier layer that stays gated. Only once the first two layers are mapped and actively managed do we look at frontier imaging, targeted drugs or protocols still under study. Each one is tagged by evidence level, anchored to a specific profile, and offered only where there's a plausible net gain beyond simply doing the basics better. The rule that went into our operating model is blunt: the impressive tools stay closed until the dull work is done. How we sequence that work is public for exactly this reason.

Paternalism is the usual accusation and it misses the mechanism. The aim is to make the business agree with what a risk model built honestly across decades would recommend, and that has consequences we live with. We can't reach our numbers by selling an infusion on arrival day to an exhausted executive whose blood pressure is too high. We have to turn prevention design, interpretation and behaviour architecture into products people will pay properly for. Retention has to come from how somebody feels and functions six months later, rather than from how impressed they were on arrival. Ethics operates here as a constraint that shapes the profit and loss account, which is a very different object from a brand value.

That's one attempt, in one geography, at building the layer this market is missing. Calling it an ethical stance overstates it. It's the only version of this business that makes sense to me if I allocate my own time and capital the way I'd want anybody to allocate health: carefully, across decades, with reality rather than narrative as the benchmark. If that's the kind of work you want done on your own risk, the application is where it starts.

Questions I get asked

Does an ethics-first model mean being against new technology?

No. The frontier is gated rather than closed. Frontier imaging, targeted drugs and protocols still under study get considered once the foundations and the prevention layer are mapped and actively managed, and only where there's a plausible net gain over doing the basics better. My objection is to the order in which these things get sold.

Is a full panel or an advanced scan always a warning sign?

Not at all. The question is indication and timing. The right investigation for the right person at the right stage is good medicine. The same investigation sold to everyone who walks in on day one is a revenue tactic. Broad screening of general populations outside defined risk groups is where epidemiologists raise concerns, because it tends to generate findings and procedures without moving mortality.

How do I apply these filters if I'm not a clinician?

You don't judge the science. You judge the structure. Can they name the evidence tier for each recommendation? Will they do the boring work before the exciting work? Where does their margin actually come from? Providers who are comfortable with all three answer quickly and without irritation.

Are longevity clinics acting in bad faith?

Mostly no, which is the whole reason I describe this as structure. Where margin sits in infusions and injectables, where internal metrics count how busy the devices are, and where staff are rewarded for upgrades, behaviour follows the incentives without anybody deciding to behave badly. That line sat in my own financial model. It's a design problem, and design problems get fixed in the model rather than in anyone's character.

What is ethical debt, in one sentence?

The accumulated gap between the product set you know would be defensible and net positive and the one you sell because it's profitable and the market currently tolerates it, compounding quietly until it crystallises as a scandal, a regulator, or the loss of your best people.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.